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The use of nicotine replacement therapy in pregnancy has been debated but evidence suggests 
that it is safer than smoking. 
A cross-sectional survey was conducted with: 1) General Practitioners and Obstetricians from 
a college database; 2) General Practitioners with a special interest in Indigenous health.  
General Practitioners had higher odds of prescribing compared to Obstetricians. Reading 
guidelines, confidence, viewing nicotine replacement therapy as safe, effective, and with good 
adherence, also significantly increased the odds of prescription. Clear guidance regarding 
safety and efficacy, with practical clinical protocols, are required in order to reduce variation 


















Smoking in pregnancy is an important risk factor for adverse pregnancy and foetal 
outcomes1. The use of Nicotine Replacement Therapy (NRT) during pregnancy has been 
debated due to the potential harmful effects of nicotine on foetal development2-4. However,  
NRT provides a slower and lower absorption rate of nicotine, compared to smoking5. Due to 
the higher metabolism of nicotine in pregnancy6, pregnant women who smoke might need a 
higher NRT dose, than non-pregnant women1,2,6.  
In the 2015 Cochrane review, NRT use during pregnancy increased cessation by 40% (RR 
1.41, 95% CI 1.03-1.93), and was not associated with any harmful effects 1In UK stop 
smoking services7, combination NRT (oral NRT combined with a nicotine patch) was more 
effective than receiving just one form of NRT (OR = 1.06, 95% CI 0.60–1.86) during 
pregnancy. 
The Royal Australian College of General Practitioners (RACGP)8 guidelines recommend that 
pregnant women who are motivated to quit, and have been unsuccessful without medication, 
should be offered NRT after discussing the relative risks and benefits.  The Royal Australian 
and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) Statement9 does 
not routinely recommend using NRT in pregnancy, yet  acknowledges that NRT might be 
used with pregnant women who are highly dependent, and unable to quit.  
International studies have found that NRT prescribing rates during pregnancy were relatively 
low, ranging from 7-55%10-13. Safety concerns and lack of training were mentioned as 




Using NRT during pregnancy is recommended to be under the supervision of a health 
professional8. None the less, NRT can be bought over the counter, and therefore for the 
purpose of this study, NRT prescription refers to either a prescription and/or a 
recommendation for NRT use.  
This study aimed to examine: 1) self-reported NRT prescription rates during pregnancy 2) the 
association between clinician-related factors including attitudes, confidence and guidelines 
awareness, and NRT prescription rate, in Australian General Practitioners (GPs) and 
Obstetricians,  
 
MATERIAL AND METHODS 
Design: A national self-administered cross-sectional survey (July to November 2015).   
Sample: Eligible participants were Australian Obstetricians or GPs with or without obstetric 
training, who confirm pregnancy or consult with pregnant women. 
Procedures: Two sampling methods were used: 1) a paper survey sent as an insert in The 
RANZCOG “O&G” magazine distributed to 5571 Obstetricians and GPs with obstetric 
training, and 2) an online survey emailed to a random sample of 500 members of the RACGP 
National Faculty of Aboriginal and Torres Strait Islander Health (members are either working 
or have a special interest in Aboriginal and Torres Strait Islander health, and/or identify as 
Aboriginal and Torres Strait Islander). The first sample did not receive a reminder. The 
second sample received one reminder after two weeks. An Information Statement was 
provided with survey completion assumed consent. An incentive of a draw of one of two 
mini-tablet devices was offered. The University of Newcastle Human Research Ethics 
Committee approved the study (#H-2015-0067, 18/03/2015). 
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Survey: Included questions about participant’s characteristics, self-reported provision of 
smoking cessation care, including NRT prescription; factors associated with prescribing NRT 
in pregnancy; and a self-assessment of barriers and enablers to providing smoking cessation 
care. The full survey description can be found elsewhere14. Results presented here include 
self-reported prescription of NRT and factors related to prescribing NRT in pregnancy.  
Participant characteristics: included gender, years since medical qualification, smoking 
status, population their medical practice mostly caters for (general or Aboriginal and Torres 
Strait Islander), and work location postcode (for rural, remote and urban classification)15. 
Frequency of prescribing NRT: A 5-point Likert scale was used  -  Never (0%); Occasional 
(1-25%); Sometimes (26-50%); Often (51-75%); Always (76-100%). Another set of 
questions, with the same Likert Scale, asked specifically the prescription rates of a) oral 
forms, b) patches and c) combination NRT. 
Clinician factors associated with prescribing NRT: Clinicians were asked to rate the 
following factors - perceived safety, effectiveness and women’s adherence of NRT. Self-
reported confidence (to prescribe) was measured using a 5-point Likert Scale (strongly 
disagree to strongly agree).  An additional question assessed reading the RACGP guidelines 
Yes/No.  
Analysis: was performed with SPSS v24. A descriptive analysis used counts and percentages. 
Univariate analysis was performed using Pearson’s Chi-square test for categorical measures 
(with post-hoc comparisons using Bonferroni correction), and Kruskal-Wallis for ordinal 
measures, to examine the association between all clinician factors (physician group – 
RACGP GPs, RANZCOG GPs, Obstetricians; perceived NRT safety, effectiveness, and 
adherence; confidence; and reading the RACGP guidelines) and NRT prescription frequency. 
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Separate ordinal regressions were performed to examine the associations between each 
clinician factor listed above on NRT prescription frequency, adjusted for gender and years 
from medical qualification to account for possible confounding. 
 
RESULTS  
Sample characteristics: 378 clinicians completed the survey (42 RACGP GPs, 157 
RANZCOG GPs and 178 Obstetricians, 1 missing the answer regarding specialty; response 
rate 6.2%), from all Australian states and territories.  Most GPs (81.4% (n=162) had obstetric 
training, 97.5% (n=153) of RANZCOG GPs, and 21.4% (n=9) of RACGP GPs. A full 
description can be found elsewhere14. 
Prescription of NRT and clinician factors associated with prescribing NRT 
 ‘Never’ prescribing NRT was reported by 25.1% (n=93), more so by Obstetricians (38.9%, 
n= 68) compared to RACGP GPs (12.2%, n=5, p<0.001), and RANZCOG GPs (13%, n=20, 
p<0.001). Nearly half (49.9%, n=181) reported ‘never’ prescribing combination NRT, fewer 
RACGP GPs (30%, n=12), compared to Obstetricians (58.1%, n=100, p<0.001) and 
RANZCOG GPs (45.7%, n=69, p=0.004).  
Clinician factors associated with NRT prescribing are presented in Table 1. 
 
Associations between clinician factors and prescription of NRT: 
Table 2 details the crude and adjusted Odds Ratio (OR) for prescribing NRT using ordinal 
regression analyses. RACGP GPs (adjusted OR 4.1, 95% CI 2.2-7.7, p<0.001) and 
RANZCOG GPs (adjusted OR 3.45, 95% CI 2.3-5.1, p<0.001) had higher odds of NRT 
prescription, compared to Obstetricians. Reading the RACGP guidelines, confidence to 
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prescribe NRT, viewing NRT as safe, effective, and with good adherence, were also 
significantly associated with higher odds of NRT prescription.  
DISCUSSION 
Main findings: 25% of participants reported ‘never’ prescribing NRT during pregnancy. 
Nearly half (49.9%) reported they ‘never’ prescribe combination NRT. Being an Obstetrician, 
low confidence, and uncertainty over NRT safety, effectiveness and adherence, were all 
independently associated with lower odds of prescribing NRT.  
Comparison with the literature: These findings are consistent with previous international 
studies showing low levels of NRT prescription and low levels of confidence, associated 
particularly with safety concerns11,13,16-19. The low frequency of NRT prescription could 
partly be explained by the lack of a strong evidence base on the effectiveness and safety of 
NRT in pregnancy.  
Women may hold negative views regarding NRT use during pregnancy20. Clinician’s low 
confidence might be partially attributable to their perceived ability to potentially address 
negative patient views. 
Reading the RACGP guidelines was associated with higher odds of prescribing. As these 
guidelines are more “favourable” for NRT use in pregnancy, this highlights the need for clear 
practical up-to-date guidelines that can direct clinicians’ decisions.  
Implication for policy and practice:  
Further research is needed to strengthen the evidence base regarding NRT safety and 
effectiveness in pregnancy, specifically in regard to using higher doses and combination 
NRT1. Specific training on the management of smoking during pregnancy is essential, in 
particular on ‘when’ and ‘how’ to use NRT, ‘how’ to consult on the risks versus benefit of 
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using NRT during pregnancy, and ‘how’ to proactively address patient concerns about using 
NRT. Guidelines need to be updated regularly, and be more practical. . Pregnant women 
receive information from multiple health professionals as part of their prenatal care, and a 
consistent message is crucial for changing smoking behaviour. 
A practical approach would be for clinicians to aid women to weigh up their relative risk 
versus benefit from using NRT in pregnancy. NRT provides lower levels of nicotine 
compared to smoking, and experts and guidelines agree that NRT is comparatively safer. This 
may assist in all pregnant women who smoke being offered an informed option about NRT 
treatment in a timely manner. 
Limitations and Strengths: Strengths of this study include national sampling, different 
geographical settings, and a subsample that are involved in Aboriginal and Torres Strait 
Islander Health.  A limitation of the research was the low response rate, indicating that this 
sample may not represent all Australian GPs and Obstetricians, and may reflect those more 
interested in tobacco related topics, suggesting that if anything, the results may over-estimate 
practices, and NRT prescribing rates may be lower. Another limitation is that the RANZCOG 
statement was not included as an option in the reading guidelines question, so we could not 
assess whether familiarity with this guideline impacted practice. The data presented here was 
part of a larger survey and only a few NRT specific questions were included. Further research 
should include a larger more representative sample, and a more in depth understanding of 
clinician’s attitudes, and what they need in order to change their NRT prescription rates.  
Conclusions: NRT prescription rates during pregnancy are low: more so among 
Obstetricians than GPs. Concerns over safety and low confidence are associated with lower 
odds of prescribing NRT. Training and practical detailed protocols may help change 
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